How to Get Your GLP-1 Covered by Insurance (Even If You've Been Denied)

Log into your insurance member portal and find the 'drug list' or 'formulary.' Search for Wegovy and Zepbound. You'll see one of four outcomes: covered, covered with prior auth, not covered, or excluded for weight loss.

If it's flat-out excluded for weight loss, you have two paths: get an Ozempic or Mounjaro prescription for type 2 diabetes (if you qualify clinically), or skip to the cash-pay strategies below.

Most plans require documented BMI ≥30, or BMI ≥27 with a weight-related comorbidity (hypertension, sleep apnea, pre-diabetes, dyslipidemia, PCOS). They often also require a 3–6 month documented lifestyle trial.

Have your clinician submit the prior auth with: current and historical weights, BMI, ICD-10 codes for every relevant comorbidity, prior weight-loss attempts (Weight Watchers, Noom, Optavia all count), and a statement that the patient has been counseled on diet and exercise.

You have 180 days to appeal almost any commercial denial. Your appeal letter should: (1) cite the specific denial reason, (2) quote the plan's own medical-necessity criteria back to them, (3) attach peer-reviewed evidence (the STEP-1 or SURMOUNT-1 NEJM papers), and (4) ask for a peer-to-peer review with the insurer's medical director.

Roughly 40% of first appeals succeed when filed with a peer-to-peer request. External (state) review reverses an additional 20–30% of remaining denials.

If coverage isn't possible: LillyDirect sells Zepbound vials for $499/mo to self-pay patients. NovoCare sells Wegovy at a similar tier. Both bypass the retail pharmacy and ship to your door.

Compounded semaglutide via a vetted telehealth program is $199–$329/mo. See our compounded semaglutide guide for how to evaluate pharmacies.